Latest Corcept Therapeutics Incorporated Stories
Corcept Therapeutics Incorporated (NASDAQ: CORT) today reported financial results for the third quarter ended September 30, 2008.
Corcept Therapeutics (NASDAQ: CORT) announced today that Eli Lilly and Company (Lilly) has agreed to fund studies to test the effectiveness of Corcept's selective GRII receptor antagonist, CORT 108297, in rat models of olanzapine induced weight gain.
Corcept Therapeutics Incorporated (NASDAQ: CORT) today reported financial results for the second quarter ended June 30, 2008.
- Stoppage; cessation (of labor).
- A standing still or idling (of mills, factories, etc.).